开发一个以知识为导向的联合图表注意力学习网络,并配备一个扩散模块来诊断阿尔茨海默病
Xuegang Song1, Kaixiang Shu2, Peng Yang2
1School of Biomedical Engineering, Guangzhou Medical University, Guangzhou, China; Department of Experimental Research, South China Hospital, Medical School, Shenzhen University,National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Marshall Laboratory of Biomedical Engineering, Shenzhen University, Shenzhen 518055, China.
Medical image analysis
|September 17, 2025
概括
这项研究引入了一种新的联合学习方法,用于使用脑成像数据诊断阿尔茨海默病 (AD). 该方法提高了诊断准确度,同时在多个机构中保持数据隐私.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 研究中的有限样本大小阻碍了智能诊断系统的性能.
- 多站点数据增强了样本规模,但引入了隐私和异质性挑战.
研究的目的:
- 开发一个保护隐私的,以知识为导向的联合学习网络,以从多站点结构性MRI数据中改进AD诊断.
- 在协作神经成像研究中解决数据异质性和隐私问题.
主要方法:
- 从sMRI数据中提取基于ROI的体积特征,使用多个模板.
- 整合了先前的AD知识,以识别歧视性成像特征.
- 在联合学习框架内使用注意引导扩散模块进行数据增强.
- 用一个联合图表注意力学习网络来进行AD分类.
主要成果:
- 在三个AD数据集上验证了该方法,证明了诊断准确度的提高.
- 联合学习框架成功地维护了跨站点数据隐私.
- 扩散模块通过优先考虑关键AD特征,减轻异质性,有效地合成样本.
结论:
- 开发的以知识为导向的联合图表注意力网络是优化多站点神经成像数据的有希望的工具.
- 这种方法显著提高了阿尔茨海默病诊断在临床环境中的准确性.
- 该研究强调了联合学习的潜力,以确保安全和有效的协作医学研究.
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825